Thromb-X is a Belgian biotech company. It was founded in 1991 by Professor Désiré Collen, an expert in cardiovascular disease, of the Katholieke Universiteit Leuven and head of the VIB Departement of Transgene Technology and Gene Therapy, K.U.Leuven.
Contents |
Thromb-X was founded in 1991, as a spin-off company of Katholieke Universiteit Leuven. The company was constituted jointly by K.U.Leuven R&D and Prof. Désiré Collen. In 2001 ThromboGenics Ltd., (Dublin, Ireland), became the majority shareholder of Thromb-X and Thromb-X became the R&D subsidiary of Thrombogenics. From 2001-2007 Thromb-X was run by Managing Director Jean Marie Stassen Ph.D. In 2007 Thromb-X ceased to exists as an independent legal entity as it was absorbed by the publicly listed company Thrombogenics NV.
In that period Thromb-X advanced Staphylokinase, Microplasmin, TB-402 and TB-403 into clinical development.